Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

R. Y. Zang; P. Harter; D. S. Chi; J. Sehouli; R. Jiang; C. G. Tropé; A. Ayhan; G. Cormio; Y. Xing; K. M. Wollschlaeger; E. I. Braicu; C. A. Rabbitt; H. Oksefjell; W. J. Tian; C. Fotopoulou; J. Pfisterer; A. Du Bois; J. S. Berek

doi:10.1038/bjc.2011.328

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

R. Y. Zang, P. Harter, D. S. Chi, J. Sehouli, R. Jiang, C. G. Tropé, A. Ayhan, G. Cormio, Y. Xing, K. M. Wollschlaeger, E. I. Braicu, C. A. Rabbitt, H. Oksefjell, W. J. Tian, C. Fotopoulou, J. Pfisterer, A. Du Bois, J. S. Berek

Research output: Contribution to journal › Article › peer-review

114 Scopus citations

Abstract

Background: This study aims to identify prognostic factors and to develop a risk model predicting survival in patients undergoing secondary cytoreductive surgery (SCR) for recurrent epithelial ovarian cancer. Methods: Individual data of 1100 patients with recurrent ovarian cancer of a progression-free interval at least 6 months who underwent SCR were pooled analysed. A simplified scoring system for each independent prognostic factor was developed according to its coefficient. Internal validation was performed to assess the discrimination of the model. Results: Complete SCR was strongly associated with the improvement of survival, with a median survival of 57.7 months, when compared with 27.0 months in those with residual disease of 0.1-1 cm and 15.6 months in those with residual disease of > 1 cm, respectively (P<0.0001). Progression-free interval (≤23.1 months vs >23.1 months, hazard ratio (HR): 1.72; score: 2), ascites at recurrence (present vs absent, HR: 1.27; score: 1), extent of recurrence (multiple vs localised disease, HR: 1.38; score: 1) as well as residual disease after SCR (R1 vs R0, HR: 1.90, score: 2; R2 vs R0, HR: 3.0, score: 4) entered into the risk model. Conclusion: This prognostic model may provide evidence to predict survival benefit from secondary cytoreduction in patients with recurrent ovarian cancer.

Original language	English (US)
Pages (from-to)	890-896
Number of pages	7
Journal	British Journal of Cancer
Volume	105
Issue number	7
DOIs	https://doi.org/10.1038/bjc.2011.328
State	Published - Sep 27 2011

Keywords

ovarian cancer
pooled analysis
recurrence
surgery
survival

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/bjc.2011.328

Cite this

Zang, R. Y., Harter, P., Chi, D. S., Sehouli, J., Jiang, R., Tropé, C. G., Ayhan, A., Cormio, G., Xing, Y., Wollschlaeger, K. M., Braicu, E. I., Rabbitt, C. A., Oksefjell, H., Tian, W. J., Fotopoulou, C., Pfisterer, J., Du Bois, A., & Berek, J. S. (2011). Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. British Journal of Cancer, 105(7), 890-896. https://doi.org/10.1038/bjc.2011.328

Zang, RY, Harter, P, Chi, DS, Sehouli, J, Jiang, R, Tropé, CG, Ayhan, A, Cormio, G, Xing, Y, Wollschlaeger, KM, Braicu, EI, Rabbitt, CA, Oksefjell, H, Tian, WJ, Fotopoulou, C, Pfisterer, J, Du Bois, A & Berek, JS 2011, 'Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort', British Journal of Cancer, vol. 105, no. 7, pp. 890-896. https://doi.org/10.1038/bjc.2011.328

@article{83e8d96016854ac4acdbcfbee928e043,

title = "Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort",

abstract = "Background: This study aims to identify prognostic factors and to develop a risk model predicting survival in patients undergoing secondary cytoreductive surgery (SCR) for recurrent epithelial ovarian cancer. Methods: Individual data of 1100 patients with recurrent ovarian cancer of a progression-free interval at least 6 months who underwent SCR were pooled analysed. A simplified scoring system for each independent prognostic factor was developed according to its coefficient. Internal validation was performed to assess the discrimination of the model. Results: Complete SCR was strongly associated with the improvement of survival, with a median survival of 57.7 months, when compared with 27.0 months in those with residual disease of 0.1-1 cm and 15.6 months in those with residual disease of > 1 cm, respectively (P<0.0001). Progression-free interval (≤23.1 months vs >23.1 months, hazard ratio (HR): 1.72; score: 2), ascites at recurrence (present vs absent, HR: 1.27; score: 1), extent of recurrence (multiple vs localised disease, HR: 1.38; score: 1) as well as residual disease after SCR (R1 vs R0, HR: 1.90, score: 2; R2 vs R0, HR: 3.0, score: 4) entered into the risk model. Conclusion: This prognostic model may provide evidence to predict survival benefit from secondary cytoreduction in patients with recurrent ovarian cancer.",

keywords = "ovarian cancer, pooled analysis, recurrence, surgery, survival",

author = "Zang, {R. Y.} and P. Harter and Chi, {D. S.} and J. Sehouli and R. Jiang and Trop{\'e}, {C. G.} and A. Ayhan and G. Cormio and Y. Xing and Wollschlaeger, {K. M.} and Braicu, {E. I.} and Rabbitt, {C. A.} and H. Oksefjell and Tian, {W. J.} and C. Fotopoulou and J. Pfisterer and {Du Bois}, A. and Berek, {J. S.}",

note = "Funding Information: We greatly appreciate Dr Wendi Qian at the Medical Research Council and Dr Kenneth Hatch at University of Arizona for reviewing and editing the paper; Dr Qingyi Wei at department of epidemiology of MD Anderson Cancer Center for statistical comments, reviewing and editing the paper.",

year = "2011",

month = sep,

day = "27",

doi = "10.1038/bjc.2011.328",

language = "English (US)",

volume = "105",

pages = "890--896",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

AU - Zang, R. Y.

AU - Harter, P.

AU - Chi, D. S.

AU - Sehouli, J.

AU - Jiang, R.

AU - Tropé, C. G.

AU - Ayhan, A.

AU - Cormio, G.

AU - Xing, Y.

AU - Wollschlaeger, K. M.

AU - Braicu, E. I.

AU - Rabbitt, C. A.

AU - Oksefjell, H.

AU - Tian, W. J.

AU - Fotopoulou, C.

AU - Pfisterer, J.

AU - Du Bois, A.

AU - Berek, J. S.

N1 - Funding Information: We greatly appreciate Dr Wendi Qian at the Medical Research Council and Dr Kenneth Hatch at University of Arizona for reviewing and editing the paper; Dr Qingyi Wei at department of epidemiology of MD Anderson Cancer Center for statistical comments, reviewing and editing the paper.

PY - 2011/9/27

Y1 - 2011/9/27

N2 - Background: This study aims to identify prognostic factors and to develop a risk model predicting survival in patients undergoing secondary cytoreductive surgery (SCR) for recurrent epithelial ovarian cancer. Methods: Individual data of 1100 patients with recurrent ovarian cancer of a progression-free interval at least 6 months who underwent SCR were pooled analysed. A simplified scoring system for each independent prognostic factor was developed according to its coefficient. Internal validation was performed to assess the discrimination of the model. Results: Complete SCR was strongly associated with the improvement of survival, with a median survival of 57.7 months, when compared with 27.0 months in those with residual disease of 0.1-1 cm and 15.6 months in those with residual disease of > 1 cm, respectively (P<0.0001). Progression-free interval (≤23.1 months vs >23.1 months, hazard ratio (HR): 1.72; score: 2), ascites at recurrence (present vs absent, HR: 1.27; score: 1), extent of recurrence (multiple vs localised disease, HR: 1.38; score: 1) as well as residual disease after SCR (R1 vs R0, HR: 1.90, score: 2; R2 vs R0, HR: 3.0, score: 4) entered into the risk model. Conclusion: This prognostic model may provide evidence to predict survival benefit from secondary cytoreduction in patients with recurrent ovarian cancer.

AB - Background: This study aims to identify prognostic factors and to develop a risk model predicting survival in patients undergoing secondary cytoreductive surgery (SCR) for recurrent epithelial ovarian cancer. Methods: Individual data of 1100 patients with recurrent ovarian cancer of a progression-free interval at least 6 months who underwent SCR were pooled analysed. A simplified scoring system for each independent prognostic factor was developed according to its coefficient. Internal validation was performed to assess the discrimination of the model. Results: Complete SCR was strongly associated with the improvement of survival, with a median survival of 57.7 months, when compared with 27.0 months in those with residual disease of 0.1-1 cm and 15.6 months in those with residual disease of > 1 cm, respectively (P<0.0001). Progression-free interval (≤23.1 months vs >23.1 months, hazard ratio (HR): 1.72; score: 2), ascites at recurrence (present vs absent, HR: 1.27; score: 1), extent of recurrence (multiple vs localised disease, HR: 1.38; score: 1) as well as residual disease after SCR (R1 vs R0, HR: 1.90, score: 2; R2 vs R0, HR: 3.0, score: 4) entered into the risk model. Conclusion: This prognostic model may provide evidence to predict survival benefit from secondary cytoreduction in patients with recurrent ovarian cancer.

KW - ovarian cancer

KW - pooled analysis

KW - recurrence

KW - surgery

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=80053242297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053242297&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.328

DO - 10.1038/bjc.2011.328

M3 - Article

C2 - 21878937

AN - SCOPUS:80053242297

SN - 0007-0920

VL - 105

SP - 890

EP - 896

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this